chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shingles; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 13Apr2021 at 15:00 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to food (pumpkin seed allergy) and allergy to nuts (almond allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications.  On an unknown date in 2021, the patient experienced shingles. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of shingles which included treatment with antibiotics. The clinical outcome of the event shingles was not recovered at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient developed whelps/rash on the underside of arm where injection, of Fluvirin 2010/2011 by Novartis, was given as well as on the front of both thighs.  The injection site was not raised, only a little darker than the rest of the arm.  She began itching and noticed the rash. She is unclear as to whether or not the itching was prior to shot.  She did complain of nausea and dizziness.  She will first try Benadryl. As of now, she is breathing fine.
Initial unsolicited report received from a pharmacist on 27 October 2015. This case involves a 69-year-old female patient who was vaccinated with a first dose of FLUZONE HD (batch number: UI486AA, expiration date: 24 May 2016, dose and route of administration were not reported) in left deltoid on 20 October 2015. The patient had medical history of penicillin allergy, diabetes and hypertension. Illness at time of vaccination was none reported. The patient did not receive any other vaccination within four weeks of FLUZONE HD vaccination. Concomitant medication was not reported. On 21 October 2015, one day after vaccination, the patient developed fever. On an unspecified date, the patient's blood sugars were running high. The patient required ER or doctor visit. The laboratory investigation includes finger sticks which performed on an unspecified date. Corrective treatment was not reported. The outcome of the event was unknown. Follow up information received from pharmacist on 30 November 2015. On 21 October 2015, the patient's blood sugar were running high (in 500s). List of documents held by sender: none. Follow up information received from a pharmacist on 28 December 2015. It was reported that, patient was advised by the physician to follow the sick day protocol. Patient's blood sugars returned to normal after 3 to 5 days.
This case was reported by a other health professional via call center representative and described the occurrence of shoulder pain in a 52-year-old female patient who received FLUARIX QUADRIVALENT 2018-2019 season (batch number 75TA2, expiry date 30th June 2019) for prophylaxis. On 11th September 2018, the patient received FLUARIX QUADRIVALENT 2018-2019 season (intramuscular) .5 ml. In October 2018, less than a year after receiving FLUARIX QUADRIVALENT 2018-2019 season, the patient experienced shoulder pain. On 13th November 2018, the patient experienced rotator cuff tendinitis. In January 2019, the patient experienced difficulty sleeping, stiffness shoulder and mobility decreased. On an unknown date, the patient experienced frozen shoulder. The patient was treated with meloxicam and Physical Therapy (Nos). On an unknown date, the outcome of the shoulder pain was recovering/resolving and the outcome of the rotator cuff tendinitis, frozen shoulder, difficulty sleeping, stiffness shoulder and mobility decreased were not recovered/not resolved. It was unknown if the reporter considered the shoulder pain, rotator cuff tendinitis, frozen shoulder, difficulty sleeping, stiffness shoulder and mobility decreased to be related to FLUARIX QUADRIVALENT 2018-2019 season. Additional details were reported as follows: The practice supervisor reported that a patient received FLUARIX vaccine on left deltoid. The patient was in the office on 17th October 2018 complaining of left shoulder pain. The patient was referred to an orthopedist and saw one on 13th November 2018 and was diagnosed with rotator cuff tendinitis following flu vaccine injection. The patient was prescribed meloxicam and physical therapy. The patient saw the orthopedist again in January 2019 and she had some decrease in pain, but her shoulder was getting stiffer and stiffer and she was now having trouble with any kind of motion. This was also causing her to not sleep very well. It was diagnosed that the tendinitis had progressed into frozen shoulder and she was now receiving treatment for that condition. The patient saw her general practitioner (GP) in February 2019 and the problem was continuing till the reporting time. Emergency room visit required.
pt recv vax 14FEB96 & 1AUG97 pt broke out w/a rash described as approx 25 scabbed lesions on chest, arms, legs reported that had several open lesions & a papular rash on neck;also exp mild fever & itching;
have been sick ever since; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (have been sick ever since) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (have been sick ever since). At the time of the report, ILLNESS (have been sick ever since) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications was included. No treatment drug details was provided.
On February 22 at 7:30 AM I woke up with a sore throat and nasal congestion. On February 22, I started taking Ricola drops for 7 days. On February 23, I started taking Zyrtec - D for 5 days. Additionally, on February 28 I started taking Vitamin C. The symptoms have progressively improved. Today March 1 the sore throat completely disappeared, but I am still with mild nasal congestion.
Severe neck pain with features of radiculopathy in the L side, seen in office on 10/23/18; ED visit 10/22/18 for the same symptoms.
Vaccinated on 10/31/06 with Tdap and flu shot and also received a Tb test that day. The next day she noted her arm was sore with a knot at the injection site of the Tdap. Over the next several hours the injection site became hard, hot and painful. She is also having some itching at the injection site today.  Recommended OTC Ibuprofen and cold compress for pain relief of injection site. Described s/s of severe allergic reaction and need to seek emergent medical care if she should develop any s/s.
This case was reported by a healthcare professional and described the occurrence of injection site redness in a 65-year-old female subject who was vaccinated with FLULAVAL. The subject's medical history included cholesterol, hypertension, and allergy to BIAXIN. Concurrent medications included TOPROL, LIPITOR and Aspirin (Baby ASA). On 14 October 2008 the subject received unspecified dose of FLULAVAL (unknown, unknown arm). In October 2008, less than one week after vaccination with FLULAVAL, the subject experienced injection site redness, injection site pruritis and warmness to touch at injection site. At the time of reporting the events were unresolved. The healthcare professional considered the injection site pruritis and warmness to touch at injection site were probably related to vaccination with FLULAVAL. An office manager reports that an adult female reported redness, itching and warm to touch in her arm following FLULAVAL injection on Oct 14th.  The office manager reported that one other subject experienced adverse events following administration of FLULAVAL. Please see case A0754164A.  Follow-up information was reported on 10 November 2008, via healthcare professional who reported the subject on 14 October 2008 the subject received unspecified dose of FLULAVAL (unknown, left deltoid). On 15 October 2008, 1 day after vaccination with FLULAVAL, the subject experienced redness measuring 8 centimeters by 4.5 centimeters (very large), red and indurated skin local reaction; the subject had no bronchospasm. The subject has had flu vaccines for years and never had a reaction before. The subject was advised to use cortisone cream at injection site and BENADRYL two 5mg, once daily for itching and two ADVIL three times daily for inflammation. On 31 October 2008, the events were resolved. The subject was advised "thimerasol from flu vaccine". The healthcare professional considered the events were related to vaccination with FLULAVAL.
Patient developed Shingles about a week after the 2nd dose of Moderna Vaccine.
Complained of nausea the morning follow vaccine administered and again at bedtime, headache and diarrhea x's 1
fever; Both feet started feeling tingly; 2 big toes on both feet felt numb; numbing on left cheek; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), PARAESTHESIA (Both feet started feeling tingly), HYPOAESTHESIA (numbing on left cheek) and HYPOAESTHESIA (2 big toes on both feet felt numb) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, the patient experienced HYPOAESTHESIA (numbing on left cheek). On 20-Mar-2021, the patient experienced PYREXIA (fever), PARAESTHESIA (Both feet started feeling tingly) and HYPOAESTHESIA (2 big toes on both feet felt numb). At the time of the report, PYREXIA (fever), PARAESTHESIA (Both feet started feeling tingly), HYPOAESTHESIA (numbing on left cheek) and HYPOAESTHESIA (2 big toes on both feet felt numb) outcome was unknown. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
redness and hardness at the injection site, warm to touch, larger than it was yesterday; redness and hardness at the injection site, warm to touch, larger than it was yesterday; redness and hardness at the injection site, warm to touch, larger than it was yesterday; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (redness and hardness at the injection site, warm to touch, larger than it was yesterday), VACCINATION SITE ERYTHEMA (redness and hardness at the injection site, warm to touch, larger than it was yesterday) and VACCINATION SITE INDURATION (redness and hardness at the injection site, warm to touch, larger than it was yesterday) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Mar-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Mar-2021, the patient experienced VACCINATION SITE WARMTH (redness and hardness at the injection site, warm to touch, larger than it was yesterday), VACCINATION SITE ERYTHEMA (redness and hardness at the injection site, warm to touch, larger than it was yesterday) and VACCINATION SITE INDURATION (redness and hardness at the injection site, warm to touch, larger than it was yesterday). At the time of the report, VACCINATION SITE WARMTH (redness and hardness at the injection site, warm to touch, larger than it was yesterday), VACCINATION SITE ERYTHEMA (redness and hardness at the injection site, warm to touch, larger than it was yesterday) and VACCINATION SITE INDURATION (redness and hardness at the injection site, warm to touch, larger than it was yesterday) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.
commonplace erythema around the injection site BUT THIS HAS PROGRESSED TO A FIGURATE ERYTHEMA OF THE ERYTHEMA ANNULARE CENTRIFUGUM TYPE Can I upoload a photo to you??
(R) parotid gland swelling and rashes over (R) face. MMR given as was not immune to Mumps.
7 days after receiving 1st vaccination a lump formed (swollen lymph node) just north of clavicle bone on right shoulder area. Very sore and tender.  Aching shoulder radiating to scapula.  Itching on vaccine site of right shoulder.
Pt vaccinated with DTP/OPV experienced crying excessive x 7 hrs & swelling about 3 cm of inject site; Seen by MD dx as reaction to pertussis. No more pertussis vaccine.
Information was received from manufacturer (manufacturing control number 2015342700) on 13-OCT-2015. This spontaneous report as received from a nurse refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On an unknown date, the patient was vaccinated with PNEUMOVAX23 (unknowns strength, route and dose). On an unknown date the patient experienced localized reaction of redness and bruising at the injection site after receiving PNEUMOVAX23. The reporter further enquired if they can get PREVNAR13. The outcome of the events was unknown. Causality assessment was not provided. Additional information has been requested.
pharmacist looking for a different Rx refill in patient profile on 03/21/22 found out he got three doses of shingrix, 09/04/21, 11/5/21, and 2/5/22. The customer came on 2/5/22  fill a consent form by specifying it dose number two shingrix and was given accordingly.  We tried to contact him, he came on 3/28, we explained the situation,  he thought it was a second dose on 02/5/22. He didn't have any adverse effect.
Two days after shot 1, I experienced very loud, high pitched, bilateral tinnitus. It has significantly decreased my quality of life and I'm now struggling with anxiety and depression due to it. I have never had tinnitus before and am otherwise perfectly healthy - no structural issues to the ear, no hearing loss, etc. The vaccine caused it. I will not be getting a second shot, especially as there is still limited information available.
No additional AE; inadvertent administration of VAXELIS and ROTATEQ after TE; This spontaneous report has been received from a consumer referring to a 4-month-old patient of unknown gender. The patient's concomitant medication, pertinent medical history, drug reactions or allergies were not provided.      On unspecified date, rotavirus vaccine, live, oral, pentavalent (ROTATEQ) and diphtheria toxoid (+) hepatitis b virus vaccine rhbsag (yeast) (+) hib conj vaccine (ompc) (+) pertussis acellular 5-component vaccine (+) poliovirus vaccine inactivated (vero) (+) tetanus toxoid (VAXELIS), experienced 2 temperature excursions, one at 65.2 F for 9 hours and 45 minutes and another one at 32.4 F for 42 hours and 45 minutes. On 01-MAY-2023, the patient was inadvertently vaccinated with a dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally (lot number: W020326, expiration date: 17-OCT-2023) and diphtheria toxoid (+) hepatitis b virus vaccine rhbsag (yeast) (+) hib conj vaccine (ompc) (+) pertussis acellular 5-component vaccine (+) poliovirus vaccine inactivated (vero) (+) tetanus toxoid (VAXELIS) (lot number: U7217AA, expiration date: 12-NOV-2024) via unspecified route for prophylaxis (strengths, exact doses and dose numbers, were not known) after the aforementioned temperature excursions (TE) (product storage error). No symptoms were reported. At the time, no additional adverse event (AE) (no adverse event).
Information has been received from a healthcare worker, medical assistant who reported that on unspecified dates, an unspecified number of unspecified patients received doses of improperly stored oral, ROTATEQ (Lot numbers, expiration dates, dose and route were not reported). No adverse experiences were reported. This is one of several reports received from the same source. Additional information has been requested.
Moderna COVID-19 Vaccine EUA  I got a headache which felt similar to a tension headache within 15 minutes of getting the vaccine. Within 2 1/2 hours the headache had become a migraine and I had to lay down.
Soreness, pain at injection site within 4.5-5.0 hrs. Bump at injection site, no redness, heat at site. Now has numbness/tingling down into fingers, and soreness up into neck on injection side. "Moving my arm like to carry groceries or put my hand thru a sleeve is increasingly painful."
This case was reported by a healthcare professional and described the occurrence of asthmatic attack in a 15-month-old male subject who was vaccinated with PEDIARIX. Concurrent medical conditions included asthma and gluten intolerance. Previous and/or concurrent vaccination included PEDIARIX, GlaxoSmithKline unknown; unknown given on 14 September 2009; mmr vaccine (non-gsk); Merck;unknown; unknown. On 12 November 2009 the subject received 2nd dose of PEDIARIX (.5ml, unknown, left thigh). On 13 November 2009, one day after vaccination with PEDIARIX, the subject experienced asthmatic attack. The healthcare professional considered the event was disabling. At the time of reporting the outcome of the asthma attack was resolved. The healthcare professional considered the events was possibly related to vaccination with PEDIARIX.
2 weeks after receiving immunization patient developed a new onset of right lower abdominal pain, diagnosed with panniculitis via CT scan. Patient questions possible correlation.
gland under that armpit is swollen and very sore; gland under that armpit is swollen and very sore; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 17Apr2021 at 17:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, obesity and high cholesterol. The patient had no allergies to medications, food, or other products. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and prednisone (MANUFACTURER UNKNOWN), both taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 13Mar2021 at 11:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 09:30, a day after the shot on her right arm, the patient experienced that the gland under the right armpit was swollen and very sore. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event gland under the right armpit was swollen and very sore was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
This spontaneous report was received from a pharmacist via company representative and refers to a female patient of unknown age. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On an unknown date in 2017, a few weeks ago, the patient was vaccinated with PNEUMOVAX 23 (dose, frequency, lot# and expiration date were not reported). On an unknown date in 2017, after administration of PNEUMOVAX23, the patient fainted and was taken to an unspecified Emergency Room. It was unknown if the patient was admitted to the hospital from the Emergency Room. The reporter stated that the patient was recovered on an unspecified date. No causality assessment was provided by reporter.
Left neck pain and intense left sided jaw pain (parotid gland area). The pain made it difficult to open mouth for 2 weeks, but it started getting better after week 1. The pain went into left ear.
pt recv vax & devel severe stinging @ site, urticaria (interdigital) & edema & dystonic/myoclonic involuntary movements;resolved w/o further tx;
Per mom, evening 8/9/04: noted a little swelling; itched. On Wednesday 8/10/04 continued to get larger red areas and hot to touch. No fever. No nausea. No vomiting, acted fine- mom thought was topical reaction (DPAT given 8/9/04 in left thigh). mom called on 8/11/04: to notify red and swollen chest. PA evaluated pt and started on Augmentin ER because because swelling had decreased and redness larger, warm to touch.
Per ER Notes: Patient is a 24 y.o. female who presents concerned about possible reaction to chickenpox shot left arm. Since the shot she is experiencing redness swelling and pain and warmth in the area. It's involving the left tricep area. The pain is moderate in severity worse with range of motion. Denies alleviating factors. She feels as though she may have had a low-grade temperature. Also with complaints of some aches and pains.
This spontaneous report as received from a Registered Nurse refers to a patient of unknown age and gender. Medical history and concurrent conditions were not provided. On 01-JUN-2015, the patient was inadvertently vaccinated with an improperly stored dose of GARDASIL lot # K009482 expiry dale: 06-MAR-2017 (dose and route were not reported). No adverse effects reported or Product Quality Complaints (PQC) involved. There was no concomitant medication provided. This is one of several reports received from the same reporter. Additional information is not expected because the reporter refused additional contact.
Pt received dose #1 Moderna COVID vaccine 1/30/21 @ Vaccine Clinic. Presented to ED with local skin reaction to the left shoulder 2/2/21 @ 1100. Discharged with OTC Zyrtec, no escalation of care. Entered by PSS for tracking.
Rapid heart rate (about 110 bpm) for 45 mins to one hour that began about 12 hours after injection
Mild nausea began at approximately 6:30pm, chills and shivering began at approximately 7:15pm. Shivering subsided by 8:30pm, headache and muscle aches persisted. No treatments administered.
Localized reaction at injection site right del itching and burning beginning 7 day post injection, also headache. Txd symptoms with Benadryl, Tylenol, Hydrocortisone cream.
where prevnar immunization given, area got very swolledn, red - larger than quater size, fever 100.3.  could hardly walk, swelling slasing going down- redness gone but small lump still in area of thigh, baby still has lump on thigh and doctor does not think its important to see baby. baby is still having trouble walking
Received TDAP vaccine 3/19/09. Developed sore arm within 24 hrs became indurated, red, hot in injection area around 48hrs, felt flu like (tired, achy, HA). Started getting pain and rash (diagnosed as shingles) approximately 4 days after vaccine admin. Hard to know if flu-like Sx from IZ or PRODROME still has shingles.
Fever, raised temp for about 30 hrs, headache 2 days, tired 2 days, on evening of 2nd day, arm below injection site to elbow was splotchy red, swollen, hot to touch, itchy. That lasted 24 more hours.
Injection site pain happened that night. Headache lasted for the next day and didn?t go away with Tylenol., Day 2- joint pain, body ache, and chills. Day 3 and 4 migraine was triggered by constant headache.